Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7344883: Complementing cell lines

Share

Filing Information

Inventor(s) Ronald Vogels · Menzo Jans Emco Havenga · Majid Mehtali ·
Assignee(s) Crucell Holland B.V. ·
Attorney/Agent(s) TraskBritt ·
Primary Examiner Sumesh Kalishal ·
Assistant Examiner Michael Burkhart ·
Application Number US11165697
Filing date 06/24/2005
Issue date 03/18/2008
Prior Publication Data
Predicted expiration date 11/15/2020
U.S. Classifications 435/325  · 435/455  · 435/235.1  · 435/320.1  · 435/366  ·
International Classifications C12N15861  · C12N508  · C12N510  · C12N700  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of application U.S. Ser. No. 10/002,750, filed Nov. 15, 2001, now U.S. Pat. No. 6,974,695, which is a continuation-in-part of application Ser. No. 09/713,678, filed Nov. 15, 2000, now U.S. Pat. No. 6,492,169, issued Dec. 10, 2002, the contents of all of which are incorporated by this reference.
15 Claims, 38 Drawings


Abstract

A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. Also, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, and measles virus.

Independent Claims | See all claims (15)

  1. 1. A packaging cell line capable of complementing a recombinant adenovirus based on a serotype from subgroup B said recombinant adenovirus lacking a functional E1 region, wherein said packaging cell line comprises functional E1A and E1B-21K coding sequences, and wherein said packaging cell line further comprises a functional E1B-55K coding sequence of a serotype from subgroup B, wherein at least one of the E1 coding sequence is driven by a non-adenoviral promoter.
  2. 12. A PER.C6 (ECACC deposit number 96022940) cell line, comprising an Ad35-E1B coding sequence.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4487829 Massachusetts Institute of Technology Sharp et al. Dec 1984
US4517686 La Jolla Cancer Research Foundation Ruoslahti et al. May 1985
US4578079 La Jolla Cancer Research Foundation Ruoslahti et al. Mar 1986
US4589881 La Jolla Cancer Research Foundation Pierschbacher et al. May 1986
US4593002 Salk Institute Biotechnology/Industrial Associates, Inc. Dulbecco Jun 1986
US4792525 La Jolla Cancer Research Foundation Ruoslahti et al. Dec 1988
US4797368 The United States of America as represented by the Department of Health and Human Services Carter et al. Jan 1989
US4956281 Biogen, Inc. Wallner et al. Sep 1990
US5024939 Genentech, Inc. Gorman Jun 1991
US5096815 Protein Engineering Corporation Ladner et al. Mar 1992
US5166320 University of Connecticut Wu et al. Nov 1992
US5198346 Protein Engineering Corp. Ladner et al. Mar 1993
US5204445 The Scripps Research Institute Plow et al. Apr 1993
US5223394 Biogen, Inc. Wallner Jun 1993
US5223409 Protein Engineering Corp. Ladner et al. Jun 1993
US5240846 The Regents of the University of Michigan Collins et al. Aug 1993
US5246921 The Wistar Institute of Anatomy and Biology Reddy et al. Sep 1993
US5332567 Immunomedics Goldenberg Jul 1994
US5349053 Protein Design Labs, Inc. Landolfi Sep 1994
US5403484 Protein Engineering Corporation Ladner et al. Apr 1995
US5436146 The Trustees of Princeton University Shenk et al. Jul 1995
US5443953 Immunomedics, Inc. Hansen et al. Aug 1995
US5474935 The United States of America as represented by the Department of Health and Human Services Chatterjee et al. Dec 1995
US5521291 Boehringer Ingelheim International, GmbH Curiel et al. May 1996
US5534423 Regents of the University of Michigan Plasson et al. Jul 1996
US5543328 Genetic Therapy, Inc. McClelland et al. Aug 1996
US5547932 Boehringer Ingelheim International GmbH Curiel et al. Aug 1996
US5552311 University of Alabama at Birmingham Research Foundation Sorscher et al. Sep 1996
US5559099 GenVec, Inc. Wickham et al. Sep 1996
US5571698 Protein Engineering Corporation Ladner et al. Nov 1996
US5622699 La Jolla Cancer Research Foundation Ruoslahti et al. Apr 1997
US5712136 GenVec, Inc. Wickham et al. Jan 1998
US5731190 GenVec, Inc. Wickham et al. Mar 1998
US5756086 Genetic Therapy, Inc. McClelland et al. May 1998
US5770442 Cornell Research Foundation, Inc. Wickham et al. Jun 1998
US5837511 Cornell Research Foundation, Inc. Flack-Petersen et al. Nov 1998
US5846782 GenVec, Inc. Wickham et al. Dec 1998
US5849561 Cornell Research Foundation, Inc. Falck-Pedersen Dec 1998
US5856152 The Trustees of the University of Pennsylvania Wilson et al. Jan 1999
US5871727* UAB Research Foundation Curiel Feb 1999
US5871982 The Trustees of the University of Pennsylvania Wilson et al. Feb 1999
US5877011 Genzyme Corporation Armentano et al. Mar 1999
US5880102 Duke University George et al. Mar 1999
US5922315 Genetic Therapy, Inc. Roy Jul 1999
US5994128 IntroGene B.V. Fallaux et al. Nov 1999
US5994132 University of Michigan Chamberlain et al. Nov 1999
US6033908 b.v. IntroGene Bout et al. Mar 2000
US6057155 GenVec, Inc. Wickham et al. May 2000
US6057158 Regents of the University of Michigan Chamberlain et al. May 2000
US6063622 The Regents of the University of Michigan Chamberlain et al. May 2000
US6083750 Regents of the University of Michigan Chamberlain et al. Jul 2000
US6100086 Genzyme Corporation Kaplan et al. Aug 2000
US6127525 Cornell Research Foundation, Inc. Crystal et al. Oct 2000
US6238893 Introgene B.V. Hoeben et al. May 2001
US6265212 Introgene B.V. Fallaux et al. Jul 2001
US6287857 Genzyme Corporation O'riordan et al. Sep 2001
US6306652 IntroGene B.V. Fallaux et al. Oct 2001
US6395519 IntroGene B.V. Fallaux et al. May 2002
US6486133 The Wistar Institute of Anatomy and Biology Herlyn et al. Nov 2002
US6492169 Crucell Holland, B.V. Vogels et al. Dec 2002
US6669942 Aventis Pharma S.A. Perricaudet et al. Dec 2003
US6869794* Crucell Holland, B.V. Vogels et al. Mar 2005
US6913922* Crucell Holland B.V. Bout et al. Jul 2005
US6974695* Crucell Holland B.V. Vogels et al. Dec 2005
US20020177544 AVENTIS BEHRING GMBH Haack et al. Nov 2002
US20050084480* Bout et al. Apr 2005

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
DE19754103HEPAVEC AG FUER GENTHERAPIEJun 1999
DE19918023CICHON GUENTERSep 2000
EP259212Aug 1987
EP1016726Introgene B.V.Dec 1998
EP99201545.3May 1999
EP1067188Introgene B.V.Jul 1999
EP0950713Centeon Pharma GmbHOct 1999
EP1020529Crucell Holland B.V.Nov 1999
EP0978566Crucell Holland B.V.Feb 2000
WO199100360Jan 1991
WO199105805May 1991
WO199105871May 1991
WO199202553Feb 1992
WO199213081Aug 1992
WO199303769Mar 1993
WO199306223Apr 1993
WO199307282Apr 1993
WO199307283Apr 1993
WO199408026Apr 1994
WO199410323May 1994
WO199411506May 1994
WO199415644Jul 1994
WO199417832Aug 1994
WO199424299Oct 1994
WO199426915Nov 1994
WO199505201Feb 1995
WO199506745Mar 1995
WO199514785Jun 1995
WO199516037Jun 1995
WO199521259Aug 1995
WO199526412Oct 1995
WO199527071Oct 1995
WO199531187Nov 1995
WO199531566Nov 1995
WO199600326Jan 1996
WO199600790Jan 1996
WO199607739Mar 1996
WO199610087Apr 1996
WO199612030Apr 1996
WO199613597May 1996
WO199613598May 1996
WO199614837May 1996
WO199617073Jun 1996
WO199618740Jun 1996
WO199624453Aug 1996
WO199626281Aug 1996
WO199635798Nov 1996
WO199700326Jan 1997
WO199712986Apr 1997
WO199720575THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATIONJun 1997
WO199738723Oct 1997
WO199807865Feb 1998
WO199811221Mar 1998
WO199813499Apr 1998
WO199817783Apr 1998
WO199822609May 1998
WO199832842Jul 1998
WO199840509Sep 1998
WO199849300Nov 1998
WO199850053Nov 1998
WO199932647Jul 1999
WO199947180GENZYME CORPORATIONSep 1999
WO199955132INTROGENE B.V.Nov 1999
WO199958646Nov 1999
WO200003029INTROGENE B.V.Jan 2000
WO200024730THE UNIVERSITY OF BRITISH COLUMBIAMay 2000
WO200031285INTROGENE B.V.Jun 2000
WO200052186INTROGENE B.V.Sep 2000
WO200070071INTROGENE B.V.Nov 2000
WO200104334INTROGENE B.V.Jan 2001
WO200190158CRUCELL HOLLAND B.V.Nov 2001
WO200224730CRUCELL HOLLAND B.V.Mar 2002
WO200227006CRUCELL HOLLAND B.V.Apr 2002
WO200240665CRUCELL HOLLAND B.V.May 2002
WO200240665CRUCELL HOLLAND B.V.May 2002
* cited by examiner

Other Publications

Abrahamsen et al., “Construction of an Adenovirus Type 7a E1A Vector,” Journal of Virology, Nov. 1997, p. 8946-8951 vol. 71, No. 11.
Albiges-Rizo et al., “Human Adenovirus Serotype 3 Fiber Protein,” Journal of Biological Chemistry, 266(6), 3961-3967 (1991).
Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, pp. 25-30.
Athappilly et al., “The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2 9 A Resolution,” J. Mol. Biol. (1994) 242, 430-455.
Bai et al., “Mutations That Alter an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells,” Journal of Virology, 67(9), 5198-5205 (1993).
Bailey et al., “Phylogenetic Relationships among Adenovirus Serotypes,” Virology, 205, 439-452 (1994).
Ball-Goodrich et al., “Parvoviral Target Cell Specificity: Acquisition of Fibrotropism by a Mutant of the Lymphotropic Strain of Minute Virus of Mice Involves Multiple Amino Acid Substitutions within the Capsid,” Virology, 184, 175-186 (1991).
Basler et al., Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, 1996, Gene 170:249-254.
Basler et al., “Subgroup B Adenovirus Type 35 Early Region 3 mRNAs Differ from Those of the Subgroup C Adenoviruses,” VIROLOGY 215, 165-177 (1996).
Batra et al., “Receptor-mediated gene delivery employing lectin-binding specificity,” Gene Therapy, 1, 255-260 (1994).
Berendsen, Herman J.C., A Glimpse of the Holy Grail, Science, 1998, vol. 282, pp. 642-643.
Boursnell et al., “In vitro construction of a recombinant adenovirus Ad2:Ad5,” Gene, 13, 311-317 (1981).
Bridge et al., “Adenovirus Early Region 4 and Viral DNA Synthesis,” Virology 193, 794-801 (1993).
Brody et al., “Adenovirus-Mediated in Vivo Gene Transfer,” Annals New York Academy of Sciences pp. 90-100, 1994.
Caillet-Boudin et al., “Functional and Structural Effects of an Ala to Val Mutation in the Adenovirus Serotype 2 Fibre,” J. Mol. Biol., 217, 477-486 (1991).
Chiu et al., Folding & Design, “Optimizing energy potentials for success in protein tertiary structure prediction,” May 1998, 3:223-228.
Chroboczek et al., “The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2,” Virology, 186, 280-285 (1992).
Chroboczek et al., Adenovirus Fiber, Current Topics in Microbiology and Immunology 1995;199 (pt 1) pp. 163-200.
Chu et al., “Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins,” Gene Therapy, I, 292-299 (1994).
Cotten et al., “Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels,” Proc. Natl. Acad. Sci. USA, 87, 4033-4037 (1990).
Cotten et al., “High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles,” Proc. Natl. Acad. Sci. USA, 89, 6094-6098 (1992).
Crawford-Miksza et al., “Adenovirus Serotype Evolution Is Driven by Illegitimate Recombination in the Hypervariable Regions of the Hexon Protein,” Virology, 224, 357-367 (1996).
Crawford-Miksza et al., “Analysis of 15 Adenovirus Hexon Proteins Reveals the Location and Structure of Seven Hypervariable Regions Containing Serotype-Specific Residues,” Journal of Virology, Mar. 1996, p. 1836-1844.
Crompton et al., “Expression of a foreign epitope on the surface of the adenovirus hexon,” J. Gen. Virol., 75(1), 133-139 (1994).
Crystal, Ronald G., “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,” Science, 270, 404-410 (1995).
Curiel et al., “High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes,” Human Gene Therapy, 3, 147-154 (1992).
Curiel et al., “Adenovirus enhancement of transferring-polylysine-mediated gene delivery,” Proc. Natl. Acad. Sci. USA, 88, 8850-8854 (1991).
De Jong et al., “Adenovirus Isolates From Urine of Patients with Acquired Immunodeficiency Syndrome,” The Lancet, Jun. 11, 1983 pp. 1293-1296.
De Jong et al., Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively, Journal of Clinical Microbiology, Dec. 1999, p. 3940-45, vol. 37, No. 12, American Society for Microbiology.
Defer et al., “Human Adenovirus-Host Cell Interactions: Comparative Study with Members of Subgroups B and C,” Journal of Virology, 64(8), 3661-3673 (1990).
Deonarain, “Ligand-targeted receptor-mediated vectors for gene delivery,” (1998) Expert Opin. Ther. Pat. 8: 53-69.
Dukema et al., “Transformation of Primary Rat Kidney Cells by DNA Fragments of Weakly Oncogenic Adenoviruses,” Journal of Virology, Dec. 1979, p. 943-950.
Douglas J T et al.: “Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors” Neuromusclar Disorders, Pergamon Press, GB, vol. 7, Jul. 1997, pp. 284-298, XP002079944 ISSN: 0960-8966.
Dupuit et al., “Regenerating Cells in Human Airway Surface Epithelium Represent Preferential Targets for Recombinant Adenovirus,” Human Gene Therapy, 6, 1185-1193 (1995).
Eck et al., “Gene-Based Therapy,” (1996) Goodman & Gillman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y., pp. 77-101.
Etienne-Julan et al., “The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker,” Journal of General Virology, 73, 3251-3255 (1992).
Falgout et al., “Characterization of Adenovirus Particles Made by Deletion Mutants Lacking the Fiber Gene,” Journal of Virology, 62(2), 622-625 (1988).
Henry et al., “Characterization of the Knob Domain of the Adenovirus Type 5 Fiber Protein Expressed in Escherichia coli,” Journal of Virology, 68(8), 5239-5246 (1994).
Hidaka, Chisa, et al., “CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts,” 103(4) The Journal of Clinical Investigation 579-87 (Feb. 1999).
Hierholzer et al., “Adenoviruses from Patients with AIDS: A Plethora of Serotypes and A Description of Five New Serotypes of Subgenus D (Types 43-47),” The Journal Of Infectious Diseases vol. 158, No. 4 Oct. 1988.
Hong et al., “The Amino Terminus of the Adenovirus Fiber Protein Encodes the Nuclear Localization Signal,” Virology, 185(2), 758-767 (1991).
Horvath et al., “Nonpermissivity of Human Peripheral Blood Lymphocytes to Adenovirus Type 2 Infection,” Journal of Virology, 62(1), 341-345 (1988).
Huang et al., “Upregulation of Integrins v 3 and v 5 on Human Monocytes and T Lymphocytes Facilitates Adenovirus-Mediated Gene Delivery,” Journal of Virology, 69(4), 2257-2263 (1995).
Imler et al., “Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors,” Gene Therapy, vol. 3: p. 75-84, 1996.
Jolly; viral vector systems for gene therapy, 1994, Cancer Gene Therapy, vol. 1, No. 1: 51-64.
Kang et al., “Molecular Cloning And Physical Mapping Of The Dna Of Human Adenovirus Type 35,” Acta Microbiologica Hungarica 36 (1), pp. 67-75 (1989).
Kang et al., “Relationship Of E1 And E3 Regions Of Human Adenovirus 35 To Those Of Human Adenovirus Subgroups A, C And D,” Acta Microbiological Hungarica 36 (4), pp. 445-457 (1989).
Karayan et al., “Oligomerization of Recombinant Penton Base of Adenovirus Type 2 and Its Assembly with Fiber in Baculovirus-Infected Cells,” Virology, 202, 782-795 (1994).
Kass-Eisler et al., “Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo,” Proc. Natl. Acad. Sci. USA, 90, 11498-11502 (1993).
Kmiec, “Gene Therapy,” American Scientist, vol. 87, pp. 240, 1999.
Komoriya et al., The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine,: Journal of Biological Chemistry, 266(23), 15075-15079 (1991).
Krasnykh et al.: “Generation Of Recombinant Adenovirus Vectors With Modified Fibers For Altering Viral Tropism” Journal Of Virology, The American Society For Microbiology, US, vol. 70, No. 10, Oct. 1, 1996, pp. 6839-6846, XP002067518 ISSN: 0022-538X.
Lattanzi, Laura, et al., “High Efficiency Myogenic Conversion of Human Fibroblasts by Adenoviral Vector-mediated MyoD Gene Transfer,” 101(10) J. Clin. Invest. 2119-28 (May 1998).
Lee et al., “The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector,” Gene Therapy (1995) 2, 256-262.
Levrero et al., “Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo,” Gene, 101 (1991) 195-202.
Li et al., “Genetic Relationship between Thirteen Genome Types of Adenovirus 11, 34, and 35 with Different Tropisms,” Intervirology 1991;32:338-350.
Liu et al., Molecular Basis of the inflammatory response to adenovirus vectors. Gene Therapy (2003 10, 935-40.
Maraveyas et al., “Targeted Immunotherapy B An update with special emphasis on ovarian cancer,” Acta Oncologica, 32(7/8), 741-746 (1993).
Mastrangeli et al., “Sero-Switch” Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype, Human Gene Therapy, 7, 79-87 (1996).
Mathias et al., “Multiple Adenovirus Serotypes Use v Integrins for Infection,” Journal of Virology, 68(10), 6811-6814 (1994).
Mautner et al., “Recombination in Adenovirus: DNA Sequence Analysis of Crossover Sites in Intertypic Recombinants,” Virology, 131, 1-10 (1983).
Mautner et al., “Recomination in Adenovirus: Analysis of Crossover Sites in Intertypic Overlap Recombinants,” Virology, 139, 43-52, (1984).
Merriam-Webster Dictionary (on line) retrieved from the internet
Michael et al., “Addition of a short peptide ligand to the adenovirus fiber protein,” Gene Therapy. 2, 660-668 (1995).
Michael et al., “Binding-incompetent Adenovirus Facilitates Molecular Conjugate-mediated Gene Transfer by the Receptor-mediated Endocytosis Pathway,” Journal of Biological Chemistry, 268(10), 6866-6869 (1993).
Miller et al., “Targeted vectors for gene therapy,” FASEB Journal, 9, 190-199 (1995).
Neda et al., “Chemical Modification of an Ecotropic Murine Leukemia Virus Results in Redirection of Its Target Cell Specificity,” Journal of Biological Chemistry, 266(22), 14143-14146 (1991).
Nemerow et al., “The Role of v Integrins in Adenovirus Infection,” Biology of Vitronectins and their Receptors, 177-184 (1993).
Nemerow et al., “Adenovirus entry into host cells: a role for v integrins,” Trends in Cell Biology, 4, 52-55 (1994).
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” 1994, Merz et al. (editors), Birkhauser, Boston, MA, pp. 433 and 492-495.
Novelli et al., “Deletion Analysis of Functional Domains in Baculovirus-Expressed Adenovirus Type 2 Fiber,” Virology, 185, 365-376 (1991).
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,” (1995), [Retrieved on Nov. 16, 2004] [online] Retrieved from http://www.nih.gov/news/panelrep.html.
Peteranderl et al., “Trimerization of the Heat Shock Transcription Factor by a Triple-Stranded -Helical Coiled-Coil,” Biochemistry, 31, 12272-12276 (1992).
Prince, “Gene Transfer: A Review Of Methods And Applications,” Pathology (1998), 30, pp. 335-347.
Pring-Åkerblom et al., “Sequence Characterization and Comparison of Human Adenovirus Subgenus B and E Hexons,” Virology, 212, 232-36 (1995).
Ragot et al.,: “Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice” Nature, Macmillan Journals Ltd. London, GB, vol. 361, No. 6413, 1993, pp. 647-650, XP002162515 ISSN: 0028-0836.
Rea et al., “Highly efficient transduction of human monocyte-derived dentritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.” Journal Of Immunology, 166 (8) 5236-44., Apr. 15, 2001 XP002192775.
Robbins et al., “Viral Vectors for Gene Therapy,” Pharmacol. Ther. vol. 80, No. 1, pp. 35-47, 1998.
Roberts et al., “Three-Dimensional Structure of the Adenovirus Major Coat Protein Hexon,” Science, 232, 1148-51 (1986).
Roelvink et al., Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F, Journal Of Virology, Oct. 1998, p. 7909-7915, vol. 72, No. 10.
Romano, “Gene Transfer in Experimental Medicine,” Drug & News Perspectives, vol. 16, No. 5, 2003, 13 pages.
Russell et al., “Retroviral vectors displaying functional antibody fragments,” Nucleic Acids Research, 21(5), 1081-1085 (1993).
Russell, “Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects,” European Journal of Cancer, vol. 30A, No. 8, pp. 1165, 1994.
Sabourin et al., “The molecular regulation of myogenesis,” (2000) Clin. Genet. 57(1): 16-25.
Schnurr et al., “Two New Candidate Adenovirus Serotypes,” Intervirology 1993;36:79-83.
Schulick et al., “Established Immunity Precludes Adenovirus-mediated Gene Transfer in Rat Carotid Arteries,” The Journal of Clinical Investigation vol. 99, No. 2, Jan. 1997, 209-219.
Segerman et al.: “Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines” Journal of Virology, The American Society for Microbiology, US, vol. 74, No. 3, Feb. 2002(200-02), pp. 1457-1467, XP002161682 ISSN: 0022-538X.
Shayakhmetov et al., “Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector,” Journal Of Virology, Mar. 2000, p. 2567-2583.
Signäs et al., “Adenovirus 3 Fiber Polypeptide Gene: Implications for the Structure of the Fiber Protein,” Journal of Virology, 53(2), 672-678 (1985).
Silver et al., “Interaction of Human Adenovirus Serotype 2 with Human Lymphoid Cells,” Virology, 165, 377-387 (1988).
Stevenson et al.; Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein, 1997, Journal of Virology, vol. 71: 4782-4790.
Stewart et al., “Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy,” EMBO Journal, 12(7), 2589-2599 (1993).
Stratford-Perricaudet LD et al.: “Widespread Long-Term Gene Transfer To Mouse Skeletal Muscles And Heart” Journal Of Clinical Investigation, New York, NY, US, vol. 90 No. 2, Aug. 1992, ISSN: 0021-9738.
Toogood et al., “The Adenovirus Type 40 Hexon: Sequence, Predicated Structure and Relationship to Other Adenovirus Hexons,” J. gen. Virol. (1989), 70, 3203-3214.
Valderrama-Leon et al., “Restriction Endonuclease Mapping of Adenovirus 35, a Type Isolated from Immunocomprised Hosts,” Journal Of Virology, Nov. 1985, p. 647-650.
Verma et al., Nature, “Gene therapy-promises, problems and prospects,” Sep. 1997, vol. 389, pp. 239-242.
Wadell, “Molecular Epidemiology of Human Adenoviruses,” Microbiology and Immunology, vol. 110 pp. 191-220, 1984.
Wagner et al., “Coupling of adenovirus to transferring-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes,” Proc. Natl. Acad. Sci. USA, 89, 6099-6103 (1992).
Watson et al., “An Antigenic Analysis of the Adenovirus Type 2 Fibre Polypeptide,” Journal of Virology, 69, 525-535 (1988).
Wickham et al., “Integrins v 3 and v 5 Promote Adenovirus Internalization but Not Virus Attachment,” Cell, 73, 309-319 (1993).
Wickham et al., “Integrin v 5 Selectively Promotes Adenovirus Mediated Cell Membrane Permeabilization,” Journal of Cell Biology, 127(1), 257-264 (1994).
Wickham et al.: “Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins,” Journal of Virology, Nov. 1997, p. 8221-8229.
Zhong et al.: “Recombinant Advenovirus Is An Efficient And Non-Pertubing Genetic Vector For Human Dendritic Cells” European Journal Of Immunology, Weinheim, DE, vol. 29, No. 3, 1999, pp. 964-972, XP000938797 ISSN: 0014-2980.
PCT International Search Report, PCT/NL01/00824, dated Jul. 19, 2002.
Van Olphen et al., “Development and Characterization of Bovine X Human Hybrid Cell Lines that Efficiently Support the Replication of Both Wild-Type Bovine and Human Adenoviruses and Those with E1 Deleted.” J. of Virol., 2002, pp. 5882-5892.
Van Olphen et al., “Characterization of Bovine Adenovirus Type 3 E1 Proteins and Isolation of E1-Expressing Cell Lines.” Virology, 2002, 295, pp. 108-118.
Schiedner et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, Human Gene Therapy, Oct. 10, 2000, pp. 2105-2116, vol. 11. No. 15.
Flomenberg et al., “Sequence and genetic Organization of Adenovirus Type 35 Early Region 3,” Journal of Virology, Nov. 1988, pp. 4431-4437, vol. 62, No. 11.
Gahery-Segard et al., “Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity,” Journal of Virology, Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Rosenfeld et al., Adenovirus-Mediated Transfer of a recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo, Science, Apr. 19, 1991, pp. 431-434, vol. 252.
Roy et al., “Circumvention of Immunity to the Adenovirus major Coat Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
Stevenson et al., “Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain,” Journal of Virology, May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet et al., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,” Human Gene Therapy, 1990, pp. 241-256, vol. 1.
Duigou et al., Replication-Competent Adenovirus Formation in 293 Cells: the Recombination-Based Rate is Influenced by Structure and Location of the Transgene Cassette and Not Increased by Overproduction of HsRad 51, Rad51-Interacting, or E2F Family Proteins, Journal of Virology, May 2005, pp. 5437-5444, vol. 79, No. 9.
Francki et al., Classification and Nomenclature of Viruses, Archives of Virology Supplementum 2, pp. 140-144, 1991.
Flomenberg et al., “Molecular Epidemiology of Adenovirus Type 35 Infections in Immunocompromised Hosts,” The Journal Of Infectious Diseases vol. 155, No. 6, Jun. 1987.
Francki et al., “Classification and Nomenclature of Viruses,” Fifth Report of the International Committee on Taxonomy of Viruses; Virology Division of the International Union of Microbiology Societies pp. 140-143, 1991.
Gall et al., “Construction and characterization of Hexon-Chimeric Adenoviruses: Specification of adenovirus serotype,” 72(12) Journal of Virology 10260-64 (1998).
Gall et al., “Adenovirus Type 5 and 7 Capsid Chimera: Fiber Replacement Alters Receptor Tropism without Affecting Primary Immune Neuuralization Epitopes,” Journal Of Virology, Apr. 1996, p. 2116-2123.
George et al., “Gene therapy progress and prospects: adenoviral vectors,” Gene Therapy (2003) 10, 1135-1141.
Gorecki, “Prospects and problems of gene therapy: an update,” (2001) Expert Opin. Emerging Drugs 6(2): 187-98.
Greber et al., “Stepwise Dismantling of Adenovirus 2 during Entry into Cells,” Cell, 75, 477-486 (1993).
Green et al., “Evidence for a repeating cross- sheet structure in the adenovirus fibre,” EMBO Journal, 2(8), 1357-1365 (1983).
Grubb et al., Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans, Nature, 371, 802-806 (1994).
Gurunathan et al., American Association of Immunologists, “CD40 Ligand/Trimer DNA Enhances Both Humoral and Cellular Immune Responses and Indicates Protective Immunity to Infectious and Tumor Challenge,” 1998, 161:4563-4571.
Han et al., “Ligand-directed retroviral targeting of human breast cancer cells,” Proc. Natl. Acad. Sci. USA, 92, 9747-9751 (1995).
He et al., “A simplified system for generating recombinant adenoviruses,” Proc. Natl. Acad. Sci. USA vol. 95, pp. 2509-2514, Mar. 1998.

Referenced By

The current document is not referenced by other documents.

Patent Family

Document NumberAssigneeInventorsIssue/Pub Date
US20050277194 VOGELS RONALD Ronald Vogels et al. Dec 2005
US7344883 Crucell Holland B.V. Ronald Vogels et al. Mar 2008
US20080199433 Crucell Holland B.V. Ronald Vogels et al. Aug 2008